Value Dossier Icon

Pharmaceutical companies with R&D in Germany – Benefit for price negotiations

Figure 1: Different price guidelines apply for the AMNOG price negotiations if ≥ 5 % of the study population are German Products with initial market entry after January 1st, 2025 are now benefiting from less strict pricing guidelines if the studies used for AMNOG benefit assessment included ≥ 5 % German patients.

2025-02-05T08:44:10+01:005. February 2025|Allgemein, AMNOG Benefit Assessment, Reimbursement|Comments Off on Pharmaceutical companies with R&D in Germany – Benefit for price negotiations

Our HospitalAnalyzer is now available!

Based on the quality assurance data of the G-BA, we provide analyses on German hospitals for your market planning. For example: What are the top hospitals for AML in remission (C92.01 according to ICD-10)? Top 5 Hospitals: University Medical Center of Johannes Gutenberg University Mainz University Hospital Giessen and Marburg, Giessen site Municipal Hospital Braunschweig

2023-01-11T13:03:43+01:0011. January 2023|Allgemein|0 Comments

GKV-FinStG cabinet decision: Power shift in favor of the statutory health insurance companies expected

The German cabinet, the coalition group of ministers,  has decided to introduce the draft bill on the financial stabilization of the statutory health insurance (GKV-FinStG) into the parliamentary process [GKV-Finanzstabilisierungsgesetz - Bundesgesundheitsministerium]. The subjects of the draft bill are amendments to the Social Code Book V, in particular sections § 35a and § 130b, which

Go to Top